Literature DB >> 15953487

Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.

W Gordon Frankle1, Rajesh Narendran, Yiyun Huang, Dah-Ren Hwang, Ilise Lombardo, Claudine Cangiano, Roberto Gil, Marc Laruelle, Anissa Abi-Dargham.   

Abstract

BACKGROUND: Postmortem studies have reported several alterations in serotonin transporter (SERT) binding parameters in patients with schizophrenia. The aim of this study was to compare SERT availability in vivo in patients with schizophrenia and matched control subjects.
METHODS: Ten medication-free patients with schizophrenia and 10 healthy subjects underwent positron emission tomography (PET) scans for 90 min after 11C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile ([11C]DASB) injection. Metabolite-corrected arterial input function was measured. Regional distribution volumes (mL/g) were derived with a two tissue compartment kinetic model. Outcome measures for SERT availability included binding potential (BP) and the specific-to-nonspecific equilibrium partition coefficient (V3''). Ten brain regions with high density of SERT and where SERT availability can be reliably quantified with [11C]DASB were included in the analysis.
RESULTS: No significant differences were observed in regional BP or V3'' between patients and control subjects. No significant relationships were observed between regional SERT availability and severity of positive, negative, and depressive symptoms.
CONCLUSIONS: This study failed to detect alterations of SERT availability in patients with schizophrenia; however, this study does not rule out the possibility that schizophrenia might be associated with alterations of SERT density in the cortical regions, where the [11C]DASB-specific binding signal is too low for reliable quantification of SERT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953487     DOI: 10.1016/j.biopsych.2005.02.028

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Authors:  Robert E Davis; Kimberly E Vanover; Yun Zhou; James R Brašić; Maria Guevara; Blanca Bisuna; Weiguo Ye; Vanessa Raymont; William Willis; Anil Kumar; Lorena Gapasin; D Ronald Goldwater; Sharon Mates; Dean F Wong
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

2.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

Review 3.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 4.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

5.  Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method.

Authors:  Hiroto Kuwabara; Mary E McCaul; Gary S Wand; Christopher J Earley; Richard P Allen; Elise M Weerts; Robert F Dannals; Dean F Wong
Journal:  J Nucl Med       Date:  2012-04-09       Impact factor: 10.057

6.  How have developments in molecular imaging techniques furthered schizophrenia research?

Authors:  Judy L Thompson; Nina Urban; Anissa Abi-Dargham
Journal:  Imaging Med       Date:  2009-12-01

7.  PET imaging of serotoninergic neurotransmission with [(11)C]DASB and [(18)F]altanserin after focal cerebral ischemia in rats.

Authors:  Abraham Martín; Boguslaw Szczupak; Vanessa Gómez-Vallejo; Sandra Plaza; Daniel Padró; Ainhoa Cano; Jordi Llop
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-28       Impact factor: 6.200

8.  2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Authors:  Ajit K Parhi; Julie L Wang; Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  J Med Chem       Date:  2007-12-04       Impact factor: 7.446

Review 9.  5-HT radioligands for human brain imaging with PET and SPECT.

Authors:  Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen
Journal:  Med Res Rev       Date:  2011-06-14       Impact factor: 12.944

Review 10.  From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.

Authors:  O D Howes; P Fusar-Poli; M Bloomfield; S Selvaraj; P McGuire
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.